Back to top
more

Biogen (BIIB)

(Real Time Quote from BATS)

$184.47 USD

184.47
96,584

-1.21 (-0.65%)

Updated Oct 7, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Alkermes Focuses on Pipeline, Depends on Partners for Funds

Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.

PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y

PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.

The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources

The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources

Celgene (CELG) Submits Application for MS Drug in Europe

Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.

Mark Vickery headshot

Top Stock Reports for Visa, Honeywell & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Honeywell (HON) and Biogen (BIIB).

Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

Key highlights of the past week are merger agreements plus regulatory and pipeline developments.

Biogen to Acquire Gene-Therapy Company Nightstar for $800M

Biogen (BIIB) to acquire gene-therapy company, Nightstar Therapeutics to accelerate entry into ophthalmology space.

Company News For Mar 5, 2019

Companies in the news are; PLCE, BIIB, NITE, ASND and TAK

AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab

AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.

Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA

The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.

Novartis In-Licenses Rights to Heart Candidate From Ionis

Novartis (NVS) in-licenses rights to develop and commercialize TQJ230 from Ionis Pharmaceuticals for treating targeted cardiovascular diseases.

AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review

AbbVie's (ABBV) new drug application for its late-stage candidate, upadacitinib, gets a priority review status from the FDA for treating rheumatoid arthritis in adult patients.

Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates

Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.

Sanghamitra Saha headshot

Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T

The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T

Mark Vickery headshot

Top Research Reports for Visa, Charter Communications & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Charter Communications (CHTR) and Biogen (BIIB).

Alkermes Sinks as FDA Refuses to Approve Depression Drug

Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).

Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.

Biogen (BIIB) Beats Revenues and Earnings Estimates in Q4

Biogen (BIIB) beat estimates both for earnings and sales in Q4. Its newest drug Spinraza performed well in the quarter.

Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN

Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips

The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips

Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards?

While sales of Biogen's (BIIB) MS franchise are expected to be stable in the fourth quarter that of Spinraza are likely to increase.

Mark Vickery headshot

Top Stock Reports for Pfizer, Biogen & Schwab

Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Biogen (BIIB) and Schwab (SCHW).